Boston, MASSACHUSETTS9 Active Studies

Chronic Lymphocytic Leukemia Clinical Trials in Boston, MASSACHUSETTS

Find 9 actively recruiting chronic lymphocytic leukemia clinical trials in Boston, MASSACHUSETTS. Connect with local research sites and explore new treatment options.

9
Active Trials
8
Sponsors
1,299
Enrolling

Recruiting Chronic Lymphocytic Leukemia Studies in Boston

RecruitingBoston, MASSACHUSETTSNCT04623541

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refract...

424 participants
Genmab
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

279 participants
Eli Lilly and Company
View Study Details
RecruitingBoston, MASSACHUSETTSNCT03824483

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and ven...

230 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06524375

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD ...

110 participants
Genentech, Inc.
View Study Details
RecruitingBoston, MASSACHUSETTSNCT04895436

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previousl...

75 participants
AbbVie
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06697184

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies....

56 participants
BeiGene
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05168930

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lympho...

45 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06849713

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small...

40 participants
Massachusetts General Hospital
View Study Details
RecruitingBoston, MASSACHUSETTSNCT04560322

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in thi...

40 participants
Massachusetts General Hospital
View Study Details

About Chronic Lymphocytic Leukemia Clinical Trials in Boston

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the blood and bone marrow that affects B lymphocytes. It is the most common type of adult leukemia. Treatment options include targeted therapies, chemotherapy, and immunotherapy.

There are currently 9 chronic lymphocytic leukemia clinical trials recruiting participants in Boston, MASSACHUSETTS. These studies are seeking a combined 1,299 participants. Research is being sponsored by Genmab, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Chronic Lymphocytic Leukemia Clinical Trials in Boston — FAQ

Are there chronic lymphocytic leukemia clinical trials in Boston?

Yes, there are 9 chronic lymphocytic leukemia clinical trials currently recruiting in Boston, MASSACHUSETTS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What chronic lymphocytic leukemia treatments are being tested?

The 9 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for chronic lymphocytic leukemia.

Data updated March 2, 2026 from ClinicalTrials.gov